BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15534620)

  • 1. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
    Rodrigues P; Hering F; Campagnari JC
    Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
    Heidenreich A; Hofmann R; Engelmann UH
    J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
    Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
    Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
    Vorreuther R; Klotz T; Engelking R
    Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
    Ozyuvaci E; Altan A; Demir C
    Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
    Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
    Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer and bone metastases. The effect of clodronate.
    Kylmälä T
    Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population.
    Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D
    Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
    J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clodronate in the management of bone metastases: a clinical study of 91 patients.
    Serkies K; Jereczek-Fossa B; Badzio A; Jassem J
    Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clodronate for treatment of bone metastases in hormone refractory prostate cancer.
    Hering F; Rodrigues PR; Lipay M
    Int Braz J Urol; 2003; 29(3):228-33. PubMed ID: 15745526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.